Is Intellia Therapeutics Stock a Buy?

Intellia Therapeutics (NASDAQ: NTLA) is a biotech company that focuses on gene editing, a relatively new technology that could allow scientists to devise therapies for otherwise impossible-to-treat conditions. The question for investors, though, is whether Intellia is the best company to invest in to benefit from this potentially lucrative market. Let's look at some of the company's most promising programs, as well as its current financial position, to determine whether Intellia's stock is worth buying today.